# DFTX Definium Therapeutics, Inc.

1. [Home](https://finlab.finance/en)
2. [U.S. Stocks](https://finlab.finance/en/stocks/us)
3. Definium Therapeutics, Inc.(DFTX)

Healthcare

28.34 USD 1D -1.14 -3.87% Close 11/20

Since 2024-12-09 +356.4%

Close 11/20

* Open

  29.14

* High

  29.51

* Low

  28.18

* Prev close

  29.48

* Volume

  3.23M

* Amplitude

  4.51%

* P/B

  4.9

52W 10.46 49.70

FinLab Studio

From Definium Therapeutics, Inc. to every stock like it

AI finds several complementary traits of Definium Therapeutics, Inc. across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

[Screen stocks like Definium Therapeutics, Inc.](https://studio.finlab.finance/en/stocks/us/DFTX)

## Is Definium Therapeutics, Inc. a buy? Fundamentals and valuation first

As of 2026-11-06

Growth: Strong, Momentum: Good, Risk / liquidity: Good; Valuation: Pricey.

Valuation Pricey Free-cash-flow yield is Average; Price / book is Expensive.

TTM P/E -9.7 N/A

Price / book 4.9 82th percentile · Expensive

Free-cash-flow yield (%) -3.7 34th percentile · Average

[US Stock Backtest in Python: Price-to-Book Ratio Strategy](https://finlab.finance/en/blog/us-stock-backtest-price-to-book-strategy)[Quality Factor Investing: A US Quality Value Backtest](https://finlab.finance/en/blog/us-quality-value-strategy)

Quality Neutral ROE, TTM is Average.

ROE, TTM (%) -38.5 20th percentile · Average

Operating margin, TTM (%) — N/A

FCF margin, TTM (%) — N/A

[Quality Factor Investing: A US Quality Value Backtest](https://finlab.finance/en/blog/us-quality-value-strategy)

Growth Strong Diluted EPS growth, TTM YoY is Top.

Revenue growth, TTM YoY (%) — N/A

Diluted EPS growth, TTM YoY (%) 139.9 86th percentile · Top

Momentum Good 240-day return is Top, but 60-day return is Average.

60-day return (%) -24.2 27th percentile · Average

240-day return (%) 211.5 99th percentile · Top

[Momentum Trading Strategy: A 12-1 Momentum Backtest](https://finlab.finance/en/blog/us-momentum-strategy)

Risk / liquidity Good 20-day dollar volume is Top, but 60-day annualized volatility is Average.

20-day dollar volume 62,052,550.0 82th percentile · Top

60-day annualized volatility (%) 60.9 62th percentile · Average

[Factor Investing Explained: 10 Classic Factors in US Stocks](https://finlab.finance/en/blog/us-factor-investing)

## Definium Therapeutics, Inc. (DFTX) today

1 quant signals active · As of 2026-11-06

* Signal [Top-quintile 6-month momentum 18 events · 60-day win rate 61.1% · +88.79 pp vs market](https://finlab.finance/en/stocks/us/DFTX#mom_lead "The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.")

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

[Overview](https://finlab.finance/en/stocks/us/DFTX#zone-position)[Peers](https://finlab.finance/en/stocks/us/DFTX#zone-peers)[Signal backtests](https://finlab.finance/en/stocks/us/DFTX#zone-evidence)

## Definium Therapeutics, Inc. (DFTX) peers and tracking

Watchlist

This page refreshes daily after the close. Add Definium Therapeutics, Inc. to your watchlist to track signal changes on your next visit.

## Definium Therapeutics, Inc. (DFTX) quant signal backtests

### Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S\&P 500.

### Top-quintile 6-month momentum

Active · now 93.5%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

[Momentum Trading Strategy: A 12-1 Momentum Backtest](https://finlab.finance/en/blog/us-momentum-strategy)

18 historical occurrences (since 2017-05-18)

Average forward return after Top-quintile 6-month momentum

20-day: Win 44.4%, Sample 18, Median -1.9%, Excess +11.4%, Beat mkt rate 44.4%

60-day: Win 61.1%, Sample 18, Median +8.1%, Excess +88.8%, Beat mkt rate 55.6%

120-day: Win 61.1%, Sample 18, Median +24.7%, Excess +115.6%, Beat mkt rate 55.6%

120 days after: historical avg +122.9%

20-day +11.2%

60-day +91.0%

120-day +122.9%

20-day

60-day

120-day

Win

44.4%

61.1%

61.1%

Sample

18

18

18

Median

-1.9%

+8.1%

+24.7%

Excess

+11.4%

+88.8%

+115.6%

Beat mkt rate

44.4%

55.6%

55.6%

Over 18 occurrences, 120-day forward avg gained 122.9%, beat the market by 115.6 pts; win rate 61.1%.

More history: Market-wide momentum baseline, Signals not active now

### Market-wide momentum baseline

> Across 100,152 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.38%, a 58.4% positive-return rate, and +3.04 percentage points of average excess return versus the S\&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S\&P 500 (^GSPC).

### Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

### 52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

11 times historically; 60-day forward avg +99.5%, win rate 90.9%, beating the market by +93.9 pts on average.

### Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

### EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

[PEAD: Post-Earnings Announcement Drift Backtest](https://finlab.finance/en/blog/us-earnings-surprise-strategy)

6 times historically; 60-day forward avg -6.8%, win rate 50.0%, beating the market by -9.8 pts on average.

## Method and limits

* Returns use us\_price:adj\_close, adjusted for splits and dividends where available.
* Excess returns use world\_index:^GSPC as the S\&P 500 benchmark proxy.
* Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
* The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
* Snapshot-only tables such as analyst consensus, DCF, us\_ratios, and us\_key\_metrics are intentionally excluded from historical evidence.
* Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.

Further reading

Browse more quantitative analysis in [U.S. Stocks](https://finlab.finance/en/stocks/us). To turn these signals into backtestable rules, read the [Quantitative Trading Guide](https://finlab.finance/en/tools/quant-trading). Definitions of the Sharpe ratio, drawdown and other quant terms are in the [Quant Glossary](https://finlab.finance/en/glossary). Calculate this stock's risk-adjusted return with the [Sharpe Ratio Calculator](https://finlab.finance/en/tools/sharpe-ratio), and to automate the signals read the [Program Trading Guide](https://finlab.finance/en/tools/program-trading).

[Stock](https://finlab.finance/en/stocks/us/DFTX)

Source: https://finlab.finance/en/stocks/us/DFTX | Data dates: ../2026-11-06
